Episode Summary
Executive Summary: Peter Atiyah and John Castelline discuss familial hypercholesterolemia (FH), its genetics, diagnosis, and treatment, then pivot to CETP inhibitors and why obicetrapib may finally succeed where prior drugs failed. They also explore how CETP inhibition may affect diabetes, lipoprotein(a), and Alzheimer’s risk—especially in APOE4 carriers—linking lipid biology to cardiovascular and brain health.
Main Topics: Familial hypercholesterolemia: definition, genetics, and clinical presentation (Priority: 5/5): FH is presented as a common autosomal dominant disorder causing lifelong LDL elevation, tendon xanthomas, arcus, and premature ASCVD. Castelline explains the main genes involved (LDLR, APOB, PCSK9) and why diagnosis is best made using family history, LDL patterns, and genetic testing. How FH is diagnosed and why children are the best diagnostic anchor (Priority: 5/5): The discussion emphasizes that pediatric cases are cleaner diagnostically because secondary causes of high LDL are rare in children. The Dutch Lipid Clinic criteria, mutation testing, and LDL thresholds are used to distinguish definite, probable, and possible FH. Treatment strategy across childhood and adulthood (Priority: 5/5): Treatment begins early, often at age 6–8 in children with definite FH, using statins and ezetimibe, with PCSK9 inhibitors and inclisiran in adults. Homozygous FH may require quadruple therapy including evinacumab and sometimes apheresis. The failed history of CETP inhibitors and why obicetrapib is different (Priority: 5/5): Castelline reviews torcetrapib’s off-target blood pressure toxicity, dalcetrapib’s failure to improve outcomes, and anacetrapib’s modest success tied to LDL lowering rather than HDL raising. Obicetrapib is described as a potent, well-tolerated CETP inhibitor with strong LDL and ApoB lowering. Potential pleiotropic benefits: diabetes, lipoprotein(a), sepsis, and brain health (Priority: 4/5): The conversation explores evidence that CETP inhibition may reduce new-onset diabetes, lower lipoprotein(a), improve sepsis resilience, and potentially benefit Alzheimer’s disease through increased apoA1 and altered brain cholesterol handling. APOE4, brain cholesterol metabolism, and Alzheimer’s risk (Priority: 5/5): They connect APOE4’s impaired cholesterol transport to Alzheimer’s and cardiovascular risk, and propose that raising apoA1 via CETP inhibition may partially compensate for APOE4-related dysfunction in the brain.
Key Arguments: FH is a highly penetrant autosomal dominant disorder, most often due to LDLR mutations, and can cause severe premature coronary disease if untreated. Children are the cleanest population for diagnosing FH because secondary causes of high LDL are uncommon, making family history plus genetics especially informative. Physical signs such as tendon xanthomas and arcus cornealis are helpful but not required for diagnosis; some genetically affected people have no stigmata. Early treatment in childhood can add 15–20 years of life expectancy compared with no treatment, according to Castelline’s experience and cohort follow-up. Statins remain first-line therapy in FH, with ezetimibe and PCSK9-targeting therapies added as needed; homozygous FH may require evinacumab and apheresis. The CETP field failed repeatedly because HDL-C was used as the surrogate marker instead of understanding mechanism and LDL/ApoB effects. Torcetrapib failed because of off-target adrenal/endothelial effects that raised blood pressure and harmed patients, not because CETP inhibition itself was invalid. Anacetrapib’s outcome benefit aligned with its LDL lowering, supporting the idea that CETP inhibition works through ApoB reduction rather than HDL raising. Obicetrapib appears promising because it is potent, orally administered, inexpensive to manufacture, and has shown strong LDL/ApoB lowering without obvious phase 1/2 toxicity. CETP inhibition may also reduce diabetes risk, likely by improving cholesterol handling in pancreatic beta cells and preserving cell viability. Low CETP activity may be protective in sepsis because HDL can act as a sink for endotoxins and remain higher during infection. In APOE4 carriers, raising apoA1 through CETP inhibition may help compensate for defective brain cholesterol transport and potentially reduce Alzheimer’s risk.
Data Points: Global ASCVD deaths: ~19 million per year - Peter cites cardiovascular disease as the leading cause of death worldwide. Cancer deaths globally: ~12–13 million per year - Used for comparison to emphasize ASCVD burden. FH prevalence estimate: ~1 in 250 - Castelline estimates prevalence of monogenic FH-related mutations in the general population. Children seen in Amsterdam pediatric lipid clinic: >2,000 - Large pediatric cohort used to study heterozygous FH. Mutation detection rate in children with clear FH phenotype: 95% - In a cohort of 220 children with three-generation elevated LDL, sequencing found a mutation in 95%. Genetic distribution in Dutch FH cohort: 95% LDLR, 4.5% APOB, 0.5% PCSK9 gain-of-function - Breakdown of causative mutations in the Dutch cohort. LDL-C threshold used clinically: 190 mg/dL - Common cutoff for suspecting FH in adults. LDL-C in severe untreated FH cases: ~300 mg/dL or higher - Typical referral bias in early lipid clinic patients and severe cases. Age to start treatment in definite FH: 6 years - Dutch national guideline for children with definite FH. Pediatric LDL goal mentioned: <130 mg/dL - Conservative target discussed for children, though speakers note it may be too high. Estimated life-years gained with early LDL intervention: 15–20 years - Castelline’s estimate for early treatment in FH. Fraction of FH patients who seem symptom-free: ~5% - Long-term Dutch cohort follow-up suggests a small minority escape clinical disease. Women among FH “escapees”: Majority - Most apparently protected FH individuals were women. Torcetrapib HDL increase: ~70% - Large HDL rise that initially misled the field. Dalcetrapib HDL increase: ~30% - Raised HDL but did not improve cardiovascular outcomes. Anacetrapib LDL reduction: ~17% - Outcome benefit was consistent with LDL lowering rather than HDL raising. Obicetrapib LDL reduction: ~50% on top of high-intensity statins - Phase 1/2 efficacy described as comparable to injectables. Obicetrapib HDL increase: ~165% - Very large HDL rise, though speakers emphasize HDL rise alone is not the therapeutic goal. Obicetrapib Lp(a) reduction: 56% at 10 mg; 43% at 5 mg - Reported from the ROSE study. CETP inhibition and diabetes risk: ~16–20% reduction in new-onset type 2 diabetes - Observed across CETP inhibitor trials/meta-analysis. Genetically determined CETP effect on LDL-C: ~0.1 mmol/L lower LDL-C per 1 µg/mL lower CETP - Mendelian randomization summary. Genetically determined CETP effect on triglycerides: ~0.1 mmol/L lower triglycerides per 1 µg/mL lower CETP - Mendelian randomization summary. Genetically determined CETP effect on Lp(a): ~2+ nmol/L lower Lp(a) per 1 µg/mL lower CETP - Mendelian randomization summary. Genetically determined CETP effect on HDL-C: ~0.2–0.25 mmol/L higher HDL-C per 1 µg/mL lower CETP - Mendelian randomization summary. Genetically determined CETP effect on blood pressure: ~0.2 mmHg lower per 1 µg/mL lower CETP - Noted as biologically unexplained. Genetically determined CETP effect on HbA1c: ~0.1 mmol/mol lower per 1 µg/mL lower CETP - Mendelian randomization summary. Obicetrapib manufacturing cost: ~$36/year at scale - Castelline says the drug is cheap to make, enabling ethical pricing. Broadway trial size: 2,400 patients - Phase 3 secondary prevention trial, 1-year duration. Brooklyn trial size: 300 patients - Phase 3 heterozygous FH trial. Prevail trial size: 9,000 patients - Large phase 3 secondary prevention outcomes trial. Prevail baseline LDL-C target: ~100 mg/dL - Designed to maximize absolute LDL reduction and event detection. Prevail exclusion threshold: LDL-C below 55 mg/dL - Patients already at very low LDL are excluded. Expected follow-up in Prevail: 3.5–4 years median - Planned to be long enough to detect full lipid-lowering benefit. CETP-related apoA1/brain hypothesis: Not quantified - Mechanistic hypothesis under study in Alzheimer’s proof-of-concept work.
Pivotal Quotes: "FH is a true autosomal dominant disease, meaning it's not sex-linked. You don't need two parents to get it. You only need one parent to get it." — John Castelline: Explaining the inheritance pattern and why FH is common in families. "The moment there's elevated triglycerides, for example, and low HDL, then you immediately have to think about something entirely different." — John Castelline: Clarifying that classic FH is primarily an isolated LDL disorder. "If you don't understand a side effect in phase two, you don't move a drug into phase three until you've understood it." — John Castelline: Critiquing the torcetrapib development failure.
Implications: If obicetrapib succeeds, it could become a cheap, oral, highly potent ApoB-lowering therapy with possible added benefits for diabetes, Lp(a), and brain health—especially relevant for FH and APOE4 carriers.
About Peter Attia Drive
Expert insight on health, performance, longevity, critical thinking, and pursuing excellence. Dr. Peter Attia (Stanford/Hopkins/NIH-trained MD) talks with leaders in their fields.